Recent data have shown that fondaparinux, a selective factor Xa inhibitor, is noninferior to enoxaparin for short-term prevention of adverse cardiovascular outcomes in patients with non-ST-segment ...
The US Food and Drug Administration (FDA) decision to approve a generic heparin derivative without clinical safety or efficacy data raises the possibility that clinical trials might not always be ...
Objective Limited economic evaluation data for rivaroxaban compared with standard of care (SoC) exists in China. The objective of this analysis was to evaluate the cost-effectiveness of rivaroxaban ...
Blood thinners are medicines that help your blood flow smoothly through your veins and arteries. They keep blood clots from forming or getting bigger. Blood clots can increase your risk of having a ...
Table 1. Landmark Phase III Clinical Trials Demonstrating the Efficacy of NOACs in Thromboembolism Prophylaxis in Patients With AF and Management of VTE AF indicates atrial fibrillation; CrCl, ...
The “2023 Guideline for the Management of Patients With Aneurysmal Subarachnoid Hemorrhage” replaces the 2012 “Guidelines for the Management of Aneurysmal Subarachnoid Hemorrhage.” The 2023 guideline ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results